| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab175581-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $109.90 | |
| Ab175581-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $519.90 | |
| Ab175581-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,299.90 | |
| Ab175581-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,079.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level < 0.01EU/μg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Lintuzumab (anti-CD33) - Primary antibody, specific to CD33, Human IgG1, Antibody of CD33 |
|---|---|
| Synonyms | CD 33 antibody | CD33 antibody | CD33 antigen (gp67) antibody | CD33 antigen antibody | CD33 molecule antibody | CD33_HUMAN antibody | FLJ00391 antibody | gp67 antibody | My9 antibody | Myeloid cell surface antigen CD33 antibody | Myeloid differentiation |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Host species | Human |
| Specificity | CD33 |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | OTHER |
| Mechanism of action | Antibody of CD33 |
| Product Description |
Lintuzumab (anti-CD33) is a humanized monoclonal antibody that targets CD33, a 67-kDa cell surface glycoprotein expressed on most myeloid leukemia cells. |
| Isotype | Human IgG1 |
|---|---|
| Light Chain Type | kappa |
| SDS-PAGE | 145.24 kDa |
| Purification Method | Protein A purified |
| Shape | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 166089-32-3 |
Lintuzumab (anti-CD33) (Ab175581) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood monocytes labelling CD33 with Lintuzumab (anti-CD33) (Ab175581) conjugated with biotin (right panel) compared with Human IgG (Biotin) (Ab180314) - Isotype Control (left panel) and detected with SA-PE (rp156150).
Lintuzumab (anti-CD33) (Ab175581) - Flow Cytometry
Flow Cytometry analysis of human peripheral blood monocytes labelling CD33 (red) with Lintuzumab (anti-CD33) (Ab175581) conjugated with biotin and detected with SA-PE (rp156150). Blue - Isotype control, Human IgG (Biotin) (Ab180314). Black - Unlabelled control, cells without incubation with primary antibody.
Lintuzumab (anti-CD33) (Ab175581) - SEC
The purity of Lintuzumab (anti-CD33) (Ab175581) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0708647 | Certificate of Analysis | Jul 24, 2024 | Ab175581 |
| ZJ24F0708646 | Certificate of Analysis | Jul 24, 2024 | Ab175581 |
| ZJ24F0708645 | Certificate of Analysis | Jul 24, 2024 | Ab175581 |
| 1. Taylor VC, Buckley CD, Douglas M, Cody AJ, Simmons DL, Freeman SD. (1999) The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2.. J Biol Chem, 274 (17): (11505-12). [PMID:10206955] [10.1021/op500134e] |
| 2. Ulyanova T, Blasioli J, Woodford-Thomas TA, Thomas ML. (1999) The sialoadhesin CD33 is a myeloid-specific inhibitory receptor.. Eur J Immunol, 29 (11): (3440-9). [PMID:10556798] [10.1021/op500134e] |
| 3. Ferlazzo G, Spaggiari GM, Semino C, Melioli G, Moretta L. (2000) Engagement of CD33 surface molecules prevents the generation of dendritic cells from both monocytes and CD34+ myeloid precursors.. Eur J Immunol, 30 (3): (827-33). [PMID:10741398] [10.1021/op500134e] |
| 4. Paul SP, Taylor LS, Stansbury EK, McVicar DW. (2000) Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2.. Blood, 96 (2): (483-90). [PMID:10887109] [10.1021/op500134e] |
| 5. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. (1992) Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies.. Cancer Res, 52 (24): (6761-7). [PMID:1458463] [10.1021/op500134e] |
| 6. Garnache-Ottou F, Chaperot L, Biichle S, Ferrand C, Remy-Martin JP, Deconinck E, de Tailly PD, Bulabois B, Poulet J, Kuhlein E et al.. (2005) Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells.. Blood, 105 (3): (1256-64). [PMID:15388576] [10.1021/op500134e] |
